PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.77 USD | +7.15% |
|
+23.62% | -18.82% |
| Apr. 15 | Morgan Stanley Adjusts Pharvaris' Price Target to $34 From $35, Keeps Overweight Rating | MT |
| Apr. 12 | Pharvaris Files Mixed Shelf | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.14B 1.23B |
|---|---|---|---|---|---|
| Net income 2024 * | -115M -123M | Net income 2025 * | -136M -146M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 282M 302M | Net cash position 2025 * | 161M 173M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-9.24
x | P/E ratio 2025 * |
-8.81
x | Employees | 82 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.31% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | +7.15% | ||
| 1 week | +23.62% | ||
| Current month | -1.47% | ||
| 1 month | +7.10% | ||
| 3 months | -22.84% | ||
| 6 months | +21.44% | ||
| Current year | -18.82% |
1 week
17.57
24.20
1 month
17.5725.19
Current year
17.5733.00
1 year
7.9333.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 15-09-29 |
| Founder | 65 | 15-09-29 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | Nov. 14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 15-09-29 | |
David Meeker
CHM | Chairman | 69 | 20-12-31 |
Robert Glassman
BRD | Director/Board Member | 62 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 22.77 | +7.15% | 82,367 |
| 24-04-24 | 21.25 | -0.19% | 34,153 |
| 24-04-23 | 21.29 | +2.01% | 88,778 |
| 24-04-22 | 20.87 | +8.92% | 50,601 |
| 24-04-19 | 19.16 | +4.02% | 133,811 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
21.26
EUR
Average target price
31.03
EUR
Spread / Average Target
+45.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.82% | 1.14B | |
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
- Stock Market
- Equities
- PHVS Stock
